イスラエル - 英語 - Ministry of Health

novartis israel ltd - brimonidine tartrate; brinzolamide - eye drops, suspension - brimonidine tartrate 2 mg/ml; brinzolamide 10 mg/ml - brinzolamide, combinations - decrease of elevated intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

イスラエル - 英語 - Ministry of Health

novartis israel ltd - siponimod as fumaric acid - film coated tablets - siponimod as fumaric acid 0.25 mg - siponimod - mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include relapsing-remitting disease, and active secondary progressive disease, in adults.

イスラエル - 英語 - Ministry of Health

novartis israel ltd - siponimod as fumaric acid - film coated tablets - siponimod as fumaric acid 2 mg - siponimod - mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include relapsing-remitting disease, and active secondary progressive disease, in adults.

イスラエル - 英語 - Ministry of Health

novartis israel ltd - asciminib as hydrochloride - film coated tablets - asciminib as hydrochloride 20 mg - asciminib - scemblix is indicated for the treatment of adult patients with:• philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp), previously treated with two or more tyrosine kinase inhibitors (tkis).• ph+ cml in cp with the t315i mutation

イスラエル - 英語 - Ministry of Health

novartis israel ltd - asciminib as hydrochloride - film coated tablets - asciminib as hydrochloride 40 mg - asciminib - scemblix is indicated for the treatment of adult patients with:• philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp), previously treated with two or more tyrosine kinase inhibitors (tkis).• ph+ cml in cp with the t315i mutation

イスラエル - 英語 - Ministry of Health

novartis israel ltd - tobramycin - eye drops - tobramycin 0.3 % - tobramycin - tobramycin - antibiotic for the treatment of superficial eye infections caused by bacteria sensitive to tobramycin.

イスラエル - 英語 - Ministry of Health

novartis israel ltd - topotecan as hydrochloride - powder for solution for infusion - topotecan as hydrochloride 4 mg/vial - topotecan - topotecan - topotecan monotherapy is indicated for the treatment of:• patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.• patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage ivb disease.patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.

イスラエル - 英語 - Ministry of Health

novartis israel ltd - diclofenac as potassium - tablets - diclofenac as potassium 50 mg - diclofenac - diclofenac - management of pain and primary dysmenorrhea, when prompt pain relief is desired.

イスラエル - 英語 - Ministry of Health

novartis israel ltd - ranibizumab - solution for injection - ranibizumab 10 mg/ml - ranibizumab - ranibizumab - treatment of patients with neovascular (wet) age-related macular degeneration (amd). treatment of adult patients with visual impairment due to diabetic macular oedema (dme) . the treatment of visual impairement due to macular oedema secondary to retinal vein occlusion (rvo). the treatment of visual impaiment due to choroidal neovascularization (cnv) . lucentis is indicated in preterm infants for: the treatment of retinopathy of prematurity (rop) with zone i (stage 1+, 2+, 3 or 3+), zone ii (stage 3+) or ap-rop (aggressive posterior rop) disease.the treatment of proliferative diabetic retinopathy (pdr)

イスラエル - 英語 - Ministry of Health

novartis israel ltd - mycophenolic acid - gastro resistant tablets - mycophenolic acid 180 mg - mycophenolic acid - myfortic is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants.